StockNews.com Begins Coverage on Agile Therapeutics (NASDAQ:AGRX)

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note released on Saturday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Stock Performance

Shares of AGRX opened at $1.46 on Friday. The stock has a fifty day moving average of $1.09 and a two-hundred day moving average of $0.81. The company has a market capitalization of $10.01 million, a PE ratio of -0.40 and a beta of 1.58. Agile Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $2.63.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter. The business had revenue of $5.72 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC lifted its position in shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after buying an additional 10,000 shares during the period. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.